Glenmark Pharmaceuticals Ltd (GLEN.NS)
9 Dec 2016
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|46||2011||Executive Chairman of the Board, Chief Executive Officer, Managing Director|
|2016||President, Chief Financial Officer|
|Director - Corporate Affairs, Executive Director|
- BRIEF-Glenmark Pharmaceuticals Sept qtr consol profit up about 11 pct
- BRIEF-Glenmark Pharma gets FDA nod for generic version of skin disorder drug
- BRIEF-Glenmark appoints Kurt Stoeckli as chief scientific officer
- Fitch Assigns Glenmark's USD Notes Final 'BB' Rating
- Fitch Assigns First-Time 'BB' Rating to Glenmark Pharmaceuticals